Literature DB >> 6091822

Lack of a causal relationship between the vasodilator effect of papaverine and cyclic AMP production in the dog basilar artery.

M Fujioka.   

Abstract

The effects of papaverine and isoprenaline on smooth muscle cells of the dog basilar artery were investigated using radioimmunoassay, electrophysiological and isometric tension recording methods. For comparative purposes, the actions of these drugs on the guinea-pig basilar artery were also examined. Papaverine and isoprenaline (1 microM and 10 microM) increased the amount of cyclic AMP in both dog and guinea-pig basilar arteries. Papaverine (up to 100 microM) and isoprenaline (up to 1 microM) had no effect on the membrane potential and membrane resistance measured by recording the amplitudes of the electrotonic potentials in smooth muscle cells of the dog and guinea-pig basilar arteries. The action potential evoked by outward current pulses after pretreatment with tetraethylammonium chloride (5-10 mM) was inhibited by papaverine (greater than 1 microM) but not by isoprenaline (up to 10 microM) in smooth muscle cells of the dog and guinea-pig basilar arteries. In the dog basilar artery, papaverine (greater than 1 microM) consistently inhibited the contractions evoked by excess concentrations of [K]o (greater than 20.2 mM) or 5-hydroxytryptamine (10 nM-10 microM), dose-dependently. Isoprenaline (1 microM) had only slight effects on the contraction evoked by low concentrations of 5-hydroxytryptamine (10 nM). In the Ca2+-free solution containing EGTA (2 mM), the contraction evoked by 5-hydroxytryptamine (10 microM) or caffeine (10 mM) was dose-dependently inhibited by papaverine (greater than 1 microM). However, isoprenaline (1 microM) had no effect on these contractions. These results indicate that the vasodilator actions of papaverine on the dog basilar artery are mainly due to inhibition of the voltage-dependent influx of Ca2+ and also to inhibition of the receptor-activated release of Ca2+ stored in the cell. Since isoprenaline increased the cyclic AMP to the same extent as papaverine but had no effect on the electrical and mechanical responses, the inhibitory actions of papaverine on this tissue may not be causally related to the increased levels of cyclic AMP induced by inhibition of phosphodiesterase.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6091822      PMCID: PMC1987191          DOI: 10.1111/j.1476-5381.1984.tb10125.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  24 in total

1.  Role of cyclic AMP in rat aortic microsomal phosphorylation and calcium uptake.

Authors:  R C Bhalla; R C Webb; D Singh; T Brock
Journal:  Am J Physiol       Date:  1978-05

2.  Interrelations between cyclic AMP, cyclic GMP and contraction in guinea pig gallbladder stimulated by cholecystokinin.

Authors:  K E Andersson; R G Andersson; P Hedner; C G Persson
Journal:  Life Sci       Date:  1977-01-01       Impact factor: 5.037

3.  Studies on the inhibition of phosphodiesterase-catalyzed cyclic AMP and cyclic GMP breakdown and relaxation of canine tracheal smooth muscle.

Authors:  J B Polson; J J Krzanowski; D F Fitzpatrick; A Szentivanyi
Journal:  Biochem Pharmacol       Date:  1978-01-15       Impact factor: 5.858

4.  An ultrasensitive method for the simultaneous determination of cyclic AMP and cyclic GMP in small-volume samples from blood and tissue.

Authors:  M Honma; T Satoh; J Takezawa; M Ui
Journal:  Biochem Med       Date:  1977-12

5.  Nonspecific relaxation of intestinal smooth muscle induced by antispasmodics and movement of Calcium ions.

Authors:  I Takayanagi; H Yamashita; Y Kasuya
Journal:  Jpn J Pharmacol       Date:  1978-04

6.  [Actions of papaverine, aspaminol and bile salts and intracellular cyclic AMP level].

Authors:  T Uruno; I Takayanagi; M Tokunaga; K Kubota; K Takagi
Journal:  Jpn J Pharmacol       Date:  1974-10

7.  Inhibition of cyclic-3',5'-nucleotide-phosphodiesterase as a possible mode of action of papaverine and similarly acting drugs.

Authors:  W R Kukovetz; G Pöch
Journal:  Naunyn Schmiedebergs Arch Pharmakol       Date:  1970

8.  Papaverine-induced inhibition of phosphodiesterase activity in various mammalian tissues.

Authors:  G Pöch; W R Kukovetz
Journal:  Life Sci I       Date:  1971-02-01

Review 9.  Cyclic nucleotides and smooth muscle.

Authors:  H P Bär
Journal:  Adv Cyclic Nucleotide Res       Date:  1974

10.  The effects of papaverine on the electrical and mechanical activity of the guinea-pig taenia coli.

Authors:  N Tashiro; T Tomita
Journal:  Br J Pharmacol       Date:  1970-07       Impact factor: 8.739

View more
  6 in total

1.  BIBN4096BS is a potent competitive antagonist of the relaxant effects of alpha-CGRP on human temporal artery: comparison with CGRP(8-37).

Authors:  Raphaela Verheggen; Katja Bumann; Alberto J Kaumann
Journal:  Br J Pharmacol       Date:  2002-05       Impact factor: 8.739

2.  Modulation of noradrenaline-induced membrane currents by papaverine in rabbit vascular smooth muscle cells.

Authors:  Q Wang; W A Large
Journal:  J Physiol       Date:  1991-08       Impact factor: 5.182

3.  The pharmacological effects of allicin, a constituent of garlic oil.

Authors:  P R Mayeux; K C Agrawal; J S Tou; B T King; H L Lippton; A L Hyman; P J Kadowitz; D B McNamara
Journal:  Agents Actions       Date:  1988-08

4.  A comparison of vasodilator activity of agents activating cyclic nucleotides with those inhibiting their metabolism in rabbit isolated ear artery.

Authors:  L M Wood; D A Owen
Journal:  Br J Pharmacol       Date:  1989-03       Impact factor: 8.739

5.  Pharmacological and histological examinations of regional differences of guinea-pig lung: a role of pleural surface smooth muscle in lung strip contraction.

Authors:  W S Wong; S L Bloomquist; A M Bendele; J H Fleisch
Journal:  Br J Pharmacol       Date:  1992-03       Impact factor: 8.739

6.  Relationship between cytosolic calcium concentration and force in the papaverine-induced relaxation of medial strips of pig coronary artery.

Authors:  H Aoki; J Nishimura; S Kobayashi; H Kanaide
Journal:  Br J Pharmacol       Date:  1994-02       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.